MX2017011237A - Alteracion del metabolismo de esteroides para el tratamiento de enfermedades dependientes de esteroides. - Google Patents

Alteracion del metabolismo de esteroides para el tratamiento de enfermedades dependientes de esteroides.

Info

Publication number
MX2017011237A
MX2017011237A MX2017011237A MX2017011237A MX2017011237A MX 2017011237 A MX2017011237 A MX 2017011237A MX 2017011237 A MX2017011237 A MX 2017011237A MX 2017011237 A MX2017011237 A MX 2017011237A MX 2017011237 A MX2017011237 A MX 2017011237A
Authority
MX
Mexico
Prior art keywords
steroid
treatment
dependent disease
altering
metabolism
Prior art date
Application number
MX2017011237A
Other languages
English (en)
Inventor
Sharifi Nima
Li Zhenfei
AUCHUS Richard
Original Assignee
Cleveland Clinic Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cleveland Clinic Found filed Critical Cleveland Clinic Found
Publication of MX2017011237A publication Critical patent/MX2017011237A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describe un método para tratar enfermedad dependiente de esteroides tal como cáncer de próstata en un sujeto que incluye administrar una cantidad terapéuticamente efectiva de un inhibidor de CYP17A t y una cantidad efectiva de un inhibidor de 5-?-reductasa al sujeto.
MX2017011237A 2015-03-06 2016-03-07 Alteracion del metabolismo de esteroides para el tratamiento de enfermedades dependientes de esteroides. MX2017011237A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562129215P 2015-03-06 2015-03-06
US201562207594P 2015-08-20 2015-08-20
PCT/US2016/021181 WO2016144871A1 (en) 2015-03-06 2016-03-07 Altering steroid metabolism for treatment of steroid-dependent disease

Publications (1)

Publication Number Publication Date
MX2017011237A true MX2017011237A (es) 2017-11-28

Family

ID=55538653

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017011237A MX2017011237A (es) 2015-03-06 2016-03-07 Alteracion del metabolismo de esteroides para el tratamiento de enfermedades dependientes de esteroides.

Country Status (11)

Country Link
US (1) US10265329B2 (es)
EP (1) EP3270967A1 (es)
JP (1) JP2018507246A (es)
CN (1) CN108112235A (es)
AU (1) AU2016229991A1 (es)
BR (1) BR112017018758A2 (es)
CA (1) CA2978454A1 (es)
IL (1) IL254177A0 (es)
MX (1) MX2017011237A (es)
SG (1) SG11201707173PA (es)
WO (1) WO2016144871A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107236015A (zh) * 2017-06-15 2017-10-10 甘肃兰药药业有限公司 一种醋酸阿比特龙还原杂质及其制备方法
US20220169672A1 (en) * 2019-02-28 2022-06-02 Purdue Research Foundation Compounds for targeted therapies of castration resistant prostate cancer
JP7644713B2 (ja) * 2019-03-06 2025-03-12 プロペラ セラピューティクス インコーポレイテッド アビラテロンプロドラッグ
CN114080225A (zh) * 2019-08-08 2022-02-22 来凯有限公司 治疗癌症的方法
US20250226061A1 (en) * 2021-07-08 2025-07-10 The Regents Of The University Of Michigan Retention Time Trajectory Matching For Peak Identification In Chromatographic Analysis
CN114649094B (zh) * 2022-03-30 2022-11-15 广东省人民医院 一种基于核磁共振的乳腺癌多参数临床决策辅助装置
CN116589519A (zh) * 2023-05-17 2023-08-15 江西川奇药业有限公司 一种醋酸阿比特龙及其中间产物的合成方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor

Also Published As

Publication number Publication date
WO2016144871A1 (en) 2016-09-15
BR112017018758A2 (pt) 2018-04-17
CA2978454A1 (en) 2016-09-15
US10265329B2 (en) 2019-04-23
EP3270967A1 (en) 2018-01-24
US20160310509A1 (en) 2016-10-27
IL254177A0 (en) 2017-10-31
AU2016229991A1 (en) 2017-10-05
SG11201707173PA (en) 2017-09-28
JP2018507246A (ja) 2018-03-15
CN108112235A (zh) 2018-06-01

Similar Documents

Publication Publication Date Title
MX2017011237A (es) Alteracion del metabolismo de esteroides para el tratamiento de enfermedades dependientes de esteroides.
MX2022001757A (es) Inhibidores de muerte programada 1 (pd-19)/ligando de muerte programada 1 (pd-l1) para el tratamiento de cancer.
PH12018500097A1 (en) Combination of pd-1 antagonist with an egfr inhibitor
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
MX2018014435A (es) Inhibidores de muerte programada 1 (pd-1) ligando de muerte programada (pd-l1) para el tratamiento de cancer.
PH12018500174A1 (en) Combined use of anti pd-1 and anti m-csf antibodies in the treatment of cancer
MX2016001901A (es) Biomarcadores para tratamiento de trastornos neoplasicos usando terapias dirigidas con andrógeno.
MX2023011187A (es) Metodos para tratar el cancer de prostata.
GEP20217317B (en) Combination therapy for the treatment of cancer
MX373231B (es) Agente anticancerigeno.
NI201900105A (es) Terapia combinada para el cáncer de próstata
IL275517A (en) Combined methods and treatment of cancer
IL254842A0 (en) Therapeutic preparations and methods for use in cancer treatment
HK1258319A1 (zh) 癌症疗法
MX2020001727A (es) Terapia de combinacion.
SG10201900564WA (en) Methods for treating cancer
MX2019013862A (es) Terapia de combinacion.
MX382044B (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estrés.
MX2019008233A (es) Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral.
TW201613610A (en) Use of ginsenoside M1 for treating lupus nephritis
WO2012135814A3 (en) Microrna29a,b,c as a tumor suppressor and sensitizing agent for chemotherapy
IL275913A (en) Methods and combined treatment for cancer treatment
WO2012135817A3 (en) Microrna 130a,b as a tumor suppressor and sensitizing agent for chemotherapy
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.
NZ724799A (en) Compositions and methods for the treatment or prevention of neurodegenerative disorders